Mulpleta

— THERAPEUTIC CATEGORIES —
  • Bleeding disorders

Mulpleta Generic Name & Formulations

General Description

Lusutrombopag 3mg; tabs.

Pharmacological Class

Thrombopoietin receptor agonist.

How Supplied

Tabs—7

Manufacturer

Generic Availability

NO

Mulpleta Indications

Indications

Thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a procedure.

Mulpleta Dosage and Administration

Adult

Start treatment 8–14 days prior to a procedure. Should undergo procedure within 2–8 days after last dose. Take with or without food. 3mg once daily for 7 days.

Children

Not established.

Mulpleta Contraindications

Not Applicable

Mulpleta Boxed Warnings

Not Applicable

Mulpleta Warnings/Precautions

Warnings/Precautions

Obtain platelet count prior to treatment and not more than 2 days prior to procedure. Increased thrombotic risk with known risk factors (eg, Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency, Protein C or S deficiency). Ongoing or prior thrombosis or absence of hepatopetal blood flow: use only if potential benefit justifies risk. Do not use to normalize platelet counts. Pregnancy: may cause fetal harm. Nursing mothers: not recommended (during and for ≥28 days after last dose).

Mulpleta Pharmacokinetics

See Literature

Mulpleta Interactions

Not Applicable

Mulpleta Adverse Reactions

Adverse Reactions

Headache; portal vein thrombosis.

Mulpleta Clinical Trials

See Literature

Mulpleta Note

Not Applicable

Mulpleta Patient Counseling

See Literature